Bevacizumab plus chemotherapy vs Avastin for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can give written consent
- You have newly diagnosed stage IIIB/C or IV non-small cell lung cancer, or lung cancer that returned
- Your lung cancer is mainly non-squamous type confirmed by pathology (biopsy or cell test)
- Your daily functioning is good: ECOG 0 or 1 (you can do most usual activities)
- Your blood counts and liver tests are within study limits (enough white cells, platelets, hemoglobin; acceptable bilirubin/AST/ALT/alkaline phosphatase)
- You have at least one measurable tumor the scans can track
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This trial tests combining an EGFR-targeted pill (like osimertinib) with the intravenous drug bevacizumab for people with advanced non-small cell lung cancer that has an EGFR mutation and has not been treated before. The goal is to see if this combination works better when guided by a special blood test that finds cancer cells.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.